Twist Bioscience's Chief Legal Officer Sold Over 14,000 Company Shares. What Does That Mean for Investors?

Dennis Cho sold 14,205 shares on May 29, 2026, for a total transaction value of ~$991,000, at a reported price of $69.75 per share. This transaction reduced Cho's direct holdings from 134,299 shares to 120,094 shares.

The Motley Fool • Jun 6, 2026

Twist Biosciences' (TWST) CEO Sold 16,000 Shares for $1.1 Million

16,470 common shares were exercised via options and disposed in the open market for a transaction value of ~$1.12 million on May 28, 2026. The transaction represented 1.91% of Emily Leproust's direct holdings at the time, reducing direct ownership to 846,872 shares.

The Motley Fool • Jun 4, 2026

3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026

Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.

Zacks Investment Research • Jun 2, 2026

Twist Bioscience to Present at William Blair 46th Annual Growth Stock Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis, CFO of Twist Bioscience will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 10:00 am Central Time in Chicago, Illinois. The presentation will be webcast live and can be accessed by visiting the “Investor Calendar”.

Business Wire • May 27, 2026

Twist Bioscience Corporation (TWST) Analyst/Investor Day Transcript

Twist Bioscience Corporation (TWST) Analyst/Investor Day Transcript

Seeking Alpha • May 26, 2026

LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery

DÜSSELDORF, Germany--(BUSINESS WIRE)--LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will integrate our ALiCE® platform with Twist's DNA manufacturing and automation capabilities to accelerate the design–build–test cycle for protein expression services—delivering experimental results back to customers' and partners' AI models faster. “AI can design n.

Business Wire • May 8, 2026

Twist Bioscience: AI Momentum Is Real, But The Easy Money Has Been Made

Twist Bioscience (TWST) delivered strong Q2 results, driven by AI-enabled drug discovery. NGS growth was soft due to a demand air pocket caused by a large customer. Growth is expected to rebound as this company's commercial test volumes ramp. Twist's fundamentals are likely to continue improving in coming quarters. Growth investments will create modest near-term margin headwinds though.

Seeking Alpha • May 7, 2026

These Analysts Boost Their Forecasts On Twist Bioscience After Q2 Results

Twist Bioscience Corporation (NASDAQ:TWST) on Monday reported a loss for its fiscal 2026 second quarter.

Benzinga • May 5, 2026

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 115,279 equity awards, consisting of 101,931 restricted stock units (“RSUs”) and up to 13,348 performance stock units (“PSUs”), will be granted to 53 recently hired individuals, in each case as an inducement material to their acceptance of employment w.

Business Wire • May 5, 2026

Twist Bioscience Corporation (TWST) Q2 2026 Earnings Call Transcript

Twist Bioscience Corporation (TWST) Q2 2026 Earnings Call Transcript

Seeking Alpha • May 4, 2026